Oracle Clinical 5.2 and Thesaurus Management System 5.2.1 released on Sept. 4th 2017

Today (Monday Sept. 4th, 2017) Oracle released the latest version of Oracle Clinical 5.2, Oracle Clinical Remote Data Capture 5.2 and Thesaurus Management System 5.2.1.

  • OC/RDC 5.2
  • TMS 5.2.1 (TMS 5.2 with patch for supporting WHODrug B3)

OC 5.2 and TMS 5.2 is primarily a technology stack upgrade from version 5.1 including some RDC bug-fixes, and hence no new functionality as such. However, TMS 5.2 comes with a patch (5.2.1) to support the new WHODrug B3 format, which was released on March 1st, 2017, and will replace the WHODrug B2 Enhanced Format. The dictionary vendor UMC will support WHODrug B2 until end of 2018.

The Technology Stack is upgraded on below tiers:


  • Oracle Database 12c Release 1 ( Enterprise Edition


Oracle Fusion Middleware 12c which includes below on the middletier:

  • Oracle Forms and Reports
  • Oracle Application Development Framework (ADF)
  • Oracle WebLogic Server

Web Client

  • Microsoft Internet Explorer 11
  • Microsoft Edge 25.x (EdgeHTML 13), on Microsoft Windows 10 only
  • Apple Safari, on the supported iOS and OS X versions and for RDC only


The new OC 5.2 and TMS 5.2.1 software is available for download on Oracle eDelivery

Documentation (release notes and user guides)




Oracle TMS to be compatible with WHO Drug B3-format

Oracle has recently announced that the TMS (Thesaurus Management System) coding system will be compliant with the new WHO Drug B3-format.

The changes needed will be made available for users six months prior to the B3-release (released on March 1st. 2017). Patches will be targeted for TMS versions 5.1.x, 5.0.1.x approximately six months before March 2017.

Latest update

OC 4.6.6/TMS 4.6.6 will not be updated to support WHO Drug type B3 and long drug names – only OC 5.1/TMS 5.1.2 and OC 5.2/TMS5.2 (expected start Sept. 2017) will support the new WHO Drug B3 format.

Note: Drug names in WHO Drug B3 allows up to 1500 characters, but only the first 200 characters will be derived from TMS to OC. The percentage of drugs names exceeding 200 chars in WHO Drug B3 is less than 3%, so the risk for truncated drug name derived back to OC is small.

Link to News on UMC’s website: